Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXT-1003 in advanced malignancies
NCT06484985Phase 1Recruiting
- Sponsor
- Axter Therapeutics
- Start
- Sep 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AXT-1003 in non-Hodgkin lymphoma (NHL) and solid tumor, sponsored by Axter Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events. Started Sep 2024; status: recruiting.
02
Drugs
AXT-1003
03
Conditions
non-Hodgkin lymphoma (NHL)solid tumor
Beyond the preview
Go deeper on NCT06484985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484985.